A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

Inclusion Criteria Concurrent Medication: Allowed: G-CSF and erythropoietin. Prophylaxis or chronic suppression/maintenance therapy with dapsone, aerosolized pentamidine, isoniazid, rifampin, fluoroquinolones, pyrazinamide, ethambutol, fluconazole, itraconazole, acyclovir, clotrimazole, nystatin, trimethoprim/sulfamethoxazole, pyrimethamine, folic acid, sulfadiazine, clindamycin, and fansidar. Concurrent Treatment: Allowed: Limited localized radiation therapy to the skin. Patients must have: Documented HIV infection. CD4 count 50 - 300 cells/mm3. Received prior AZT that has been discontinued at least 28 days prior to study entry. No active opportunistic infection requiring immediate treatment. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Signs or symptoms of peripheral neuropathy. Malabsorption or inadequate oral intake (defined as unable to eat one or more meals daily because of chronic nausea, emesis, or abdominal/oral-esophageal discomfort. Malignancy, visceral Kaposi's sarcoma, or lymphoma requiring systemic chemotherapy and/or radiotherapy within the next 48 weeks. Any grade 3 or worse laboratory or clinical abnormality. Inability to comply with protocol requirements. Concurrent Medication: Excluded: Other antiretroviral drugs. Experimental drugs. Nephrotoxic or hepatotoxic drugs. Drugs likely to cause peripheral neuropathy. Antineoplastic agents. Biologic response modifiers. Concurrent Treatment: Excluded: Radiation therapy other than limited localized therapy to skin. Patients with the following prior conditions are excluded: History of non-Hodgkin's lymphoma. Unexplained fever >= 38.5 C (101.5 F) persisting for 14 days or longer within the 28 days prior to study entry. Unexplained, chronic diarrhea (defined as 3 or more loose stools daily) persisting for 14 days or longer within the 28 days prior to study entry. History of grade 2 or worse peripheral neuropathy. Prior Medication: Excluded: Prior HIV proteinase inhibitor. Prior antiretroviral therapy other than AZT. Acute therapy for opportunistic infection within 14 days prior to study entry. Prior Treatment: Excluded: More than 3 units of blood in any 21-day period within 3 months prior to study entry. Required: Prior AZT.